PFIZER INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PFE$29.36+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Revenues by Geography
| The following presents worldwide Total revenues by geography: | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year Ended December 31, · % Change | ||||||||||||||||
| Worldwide · U.S. · International · Worldwide · U.S. · International | ||||||||||||||||
| (MILLIONS) · 2025 · 2024 · 2023 · 2025 · 2024 · 2023 · 2025 · 2024 · 2023 · 25/24 · 24/23 · 25/24 · 24/23 · 25/24 · 24/23 | ||||||||||||||||
| Operating segments: | ||||||||||||||||
| Biopharma | $61,199 | $62,400 | $58,237 | $36,708 | $38,332 | $27,749 | $24,491 | $24,068 | $30,488 | (2) | 7 | (4) | 38 | 2 | (21) | |
| Pfizer CentreOne | 1,338 | 1,146 | 1,272 | 329 | 278 | 352 | 1,010 | 868 | 920 | 17 | (10) | 18 | (21) | 16 | (6) | |
| Pfizer Ignite | 41 | 82 | 44 | 41 | 82 | 44 | — | — | — | (50) | 85 | (50) | 85 | — | — | |
| Total revenues | $62,579 | $63,627 | $59,553 | $37,078 | $38,691 | $28,145 | $25,501 | $24,936 | $31,408 | (2) | 7 | (4) | 37 | 2 | (21) | |
| The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2024 to 2025: | |||
|---|---|---|---|
| (MILLIONS) | Worldwide | U.S. | International |
| Operational growth/(decline): | |||
| Worldwide declines from Paxlovid | $(3,346) | $(2,725) | $(622) |
| Worldwide declines from Comirnaty | (1,051) | (341) | (710) |
| Worldwide growth from the Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo, Nurtec ODT/Vydura, Xtandi and the Prevnar family, partially offset by worldwide declines from Ibrance, Adcetris and Xeljanz | 2,154 | 854 | 1,299 |
| Growth in oncology biosimilars, largely due to favorable net price in the U.S. | 266 | 286 | (20) |
| Other operational factors, net | 682 | 312 | 371 |
| Operational growth/(decline), net | (1,295) | (1,613) | 318 |
| Favorable impact of foreign exchange | 247 | — | 247 |
| Total revenues increase/(decrease) | $(1,048) | $(1,613) | $565 |
See the Total Revenues––Selected Product Discussion section within MD&A for additional analysis and Note 17C.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.